CEO Executive AssistantCompanion diagnostic partnerships have become a standard feature of oncology and precision medicine drug development. For drugs whose mechanism of action is tied to a specific molecular alteration, biomarker, or patient population characteristic, FDA increasingly requires co-approval of a companion diagnostic (CDx) test that identifies the patients who will benefit from the drug. The regulatory, commercial, and operational implications of a CDx co-development partnership extend well beyond the diagnostic test itself: they affect clinical trial design, patient selection, regulatory submission strategy, commercial launch planning, and the long-term commercial infrastructure of the drug.
Pharma CEO companion diagnostic partnership time management begins with partner selection and continues through CDx launch coordination alongside the drug approval. Each phase of this extended partnership requires CEO-level governance decisions that cannot be fully delegated to the development or commercial organization because they affect the drug program’s fundamental strategic architecture.
Why CDx Partnerships Require CEO-Level Governance
A companion diagnostic co-development partnership is not a vendor relationship. It is a strategic partnership between two companies with different business models, different regulatory frameworks, and different commercial incentives, bound together for the life of the drug’s development and commercial existence. The CDx partner is simultaneously a service provider (developing and manufacturing the test), a regulatory co-applicant (filing a PMA for the diagnostic concurrent with the drug’s NDA/BLA), and a commercial partner (ensuring test availability in the markets where the drug is approved).
The asymmetric power dynamics in CDx partnerships create CEO-level governance challenges. The pharmaceutical company typically has far greater commercial resources and regulatory experience than its diagnostic partner. But the pharmaceutical company is dependent on the diagnostic company for a capability it cannot replicate internally: IVD (in vitro diagnostic) development and manufacturing under 21 CFR Part 820 (QSR for devices) or, following the transition, ISO 13485. Misaligned expectations, inadequate resource investment by the diagnostic partner, or quality problems in CDx manufacturing can delay or derail a drug approval.
CDx Partner Selection: The CEO’s Strategic Decision
Selecting the right companion diagnostic partner is one of the most consequential decisions in a precision medicine drug development program. The selection criteria must evaluate capabilities that pharmaceutical companies are not expert in assessing, requiring CEO oversight to ensure the evaluation is rigorous and the decision is strategic.
Key CDx partner selection criteria:
Platform technology fit. The CDx must be able to detect the relevant biomarker with the required analytical sensitivity, specificity, and reproducibility. The diagnostic company’s platform technology (immunohistochemistry, FISH, PCR, NGS, or liquid biopsy) must be appropriate for the biomarker and the clinical setting in which the test will be used. The CEO should ensure the science and technology fit is evaluated by qualified external experts, not just by the company’s commercial development team.
Regulatory track record. CDx development and PMA approval is a specialized regulatory process. Diagnostic companies with a track record of successful PMA approvals, particularly in the relevant diagnostic modality, have a demonstrated capability that reduces CDx program risk. The CEO should ensure the regulatory track record of each prospective partner is thoroughly evaluated.
Global laboratory footprint. If the drug is being developed for approval in multiple markets, the CDx must be available in the major markets simultaneously with drug approval. A diagnostic partner with a global laboratory network and CE marking capability for EU markets, PMDA registration capability for Japan, and the US PMA pathway provides broader geographic coverage than a US-only diagnostic company.
Commercial commitment. The diagnostic partner must be genuinely committed to investing the resources required to develop, validate, and commercialize the CDx in parallel with the drug’s timeline. A diagnostic company that views the CDx as a low-priority project with uncertain commercial value may not invest adequately in development resources. The CEO should evaluate not just the partner’s technical capability but its organizational commitment to the program.
Relationship governance fit. A CDx co-development program will run for five to ten years. The personal relationship between the pharmaceutical CEO and the diagnostic company CEO is a meaningful factor in the partnership’s long-term health. The CEO should invest in understanding the diagnostic company’s leadership and governance culture before finalizing the partnership.
The FDA’s guidance on companion diagnostics provides the regulatory framework within which CDx co-development must operate. CEOs of pharmaceutical companies entering CDx partnerships should be familiar with FDA’s expectations for co-development and co-submission.
Co-Development Agreement Governance: Protecting the Drug Program
The co-development agreement that structures the CDx partnership is a complex document covering technology access, development responsibilities, cost sharing, regulatory submission obligations, commercialization terms, and intellectual property rights. The CEO must ensure this agreement is structured to protect the drug program from diagnostic partner underperformance, while being fair and sustainable for the diagnostic partner.
Key contractual provisions requiring CEO attention:
Development milestones and remedies. The agreement should specify CDx development milestones that must be met to maintain the partnership, and remedies (cure periods, termination rights, alternative CDx strategy provisions) if milestones are missed. A diagnostic partner that falls significantly behind the drug program’s timeline creates an acute risk to the regulatory submission.
Technology access and backup provisions. If the diagnostic company fails to complete CDx development, the pharmaceutical company needs a mechanism for accessing an alternative diagnostic solution. This may involve backup laboratory developed test (LDT) arrangements, rights to transfer the CDx development to an alternative partner, or rights to the analytical validation data generated to date. The CEO should ensure the agreement provides adequate protection against CDx development failure.
PMA filing responsibility. The co-development agreement should clearly specify which party is responsible for PMA preparation and submission, what technical data the pharmaceutical company will provide, and how the two regulatory submissions will be coordinated. FDA expects the drug sponsor and the CDx sponsor to coordinate their submissions and to be prepared to respond to FDA review questions jointly.
Post-approval supply and quality obligations. After CDx PMA approval, the diagnostic company must maintain the manufacturing quality systems required by 21 CFR Part 820, ensure test supply in all markets where the drug is approved, and update the CDx for any drug label changes that affect patient selection criteria. These post-approval obligations should be clearly defined in the agreement.
For a framework on managing complex external partner relationships within the pharmaceutical CEO’s portfolio, see CRO CEO sponsor relationships.
Joint FDA Submission Coordination: The CEO’s Role
FDA reviews companion diagnostic submissions in parallel with drug submissions. For oncology drugs requiring a CDx, FDA’s Oncology Center of Excellence coordinates the drug review (NDA or BLA) with CDRH’s review of the CDx PMA. The two applications must be technically consistent: the biomarker threshold used for patient selection in the clinical trial must be the same threshold validated in the CDx PMA.
The CEO’s role in joint submission coordination:
Submission timeline alignment. The NDA/BLA and CDx PMA should be submitted contemporaneously to allow parallel review. Gaps between submissions delay the coordinated approval. The CEO must ensure the CDx development program is tracking the drug program’s timeline and that any CDx development delays are escalated immediately to allow timeline risk mitigation.
Technical consistency governance. The drug’s clinical development program and the CDx’s analytical validation must use consistent biomarker cutoffs, consistent scoring systems (for IHC tests), and consistent interpretation criteria. Any discrepancy between the drug’s clinical data and the CDx’s analytical validation creates a regulatory problem. The CEO should ensure the Joint Development Committee or equivalent cross-company governance body has a process for identifying and resolving technical consistency issues before submission.
FDA meeting coordination. Pre-submission meetings with FDA for both the drug (Type B meetings with CDER or CDER/OCE) and the CDx (Q-Sub meetings with CDRH) should be coordinated so that FDA receives consistent messages about the co-development program. The CEO should ensure the company’s regulatory affairs organization is managing this coordination.
CDx Launch Coordination: Commercial Integration
CDx approval and drug approval must be coordinated for commercial launch. A drug approved without the CDx available in the market cannot be appropriately prescribed to the labeled patient population. A CDx approved before the drug provides no immediate clinical value. The commercial launch planning must integrate CDx availability at the diagnostic lab network level with drug availability at the pharmacy or hospital level.
The CEO’s CDx launch coordination responsibilities:
Diagnostic lab network readiness. The CDx must be available at the diagnostic laboratories that serve oncology practices in the markets where the drug will be launched. Ensuring laboratory adoption of the CDx, including laboratory technical training, test kit supply, and reimbursement code availability, requires a coordinated commercial effort that the CEO must ensure is planned with adequate lead time.
Reimbursement for the CDx. CDx tests require separate reimbursement from the drug therapy. CPT code development, CMS coverage determination for the diagnostic, and payer contracts for the CDx are a separate commercial process from drug reimbursement. The CEO must ensure the market access organization is pursuing CDx reimbursement in parallel with drug payer strategy.
Patient and physician education. Physicians who will prescribe the drug must understand the CDx requirement: which patients need testing, how to order the test, how to interpret results, and how CDx-positive status determines drug eligibility. This education effort requires coordination between the pharmaceutical commercial organization and the diagnostic company’s field force.
Time Architecture for CDx Partnership Management
A practical time architecture for pharma CEO companion diagnostic partnership time management:
Monthly joint development committee review. The CEO should receive a monthly summary of the Joint Development Committee output: CDx milestone status, any technical consistency issues identified, FDA communication updates from both parties, and any resource or timeline concerns.
Quarterly strategic partnership reviews. A quarterly review with the diagnostic company CEO covering: partnership health, development timeline status, regulatory submission readiness, commercial launch planning, and any commercial or governance issues requiring CEO-level resolution.
NDA/BLA and PMA submission preparation. As submission approaches, CEO involvement in confirming joint submission readiness: CDx PMA is complete, technical consistency between the drug submission and CDx submission has been confirmed, and joint FDA pre-submission meetings are complete.
Launch readiness review. A launch readiness review six months before anticipated approval, covering CDx lab network readiness, CDx reimbursement status, physician education plan, and supply chain readiness for both the drug and the CDx.
Conclusion
Pharma CEO companion diagnostic partnership time management reflects the reality that CDx co-development is a strategic partnership that requires sustained CEO governance for its full duration. From partner selection through CDx launch coordination, the decisions that determine whether the CDx partnership succeeds are CEO-level decisions with implications for program timelines, regulatory outcomes, and commercial success. CEOs who govern CDx partnerships with the same strategic rigor they apply to their drug programs build precision medicine platforms that deliver on the promise of biomarker-directed therapy.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.